(Rac)-Vazegepant-13C,d3

(Rac)-Vazegepant-13C,d3

• UNSPSC Description: (Rac)-Vazegepant-13C,d3 is the C13 and deuterium labeled (Rac)-Vazegepant. Vazegepant (HY-134992) is the first intranasal CGRP receptor antagonist for the study the acute research of migraine[1][2].
• Target Antigen: Isotope-Labeled Compounds
• Type: Isotope-Labeled Compounds
• Related Pathways: Others
• Field of Research: Others
• Solubility: 10 mM in DMSO
• Smiles: CC1=C2NN=CC2=CC(CC(NC(N3CCC(C4=CC5=CC=CC=C5NC4=O)CC3)=O)C(N6CCN(C7CCN([13C]([2H])([2H])[2H])CC7)CC6)=O)=C1
• Molecular Weight: 642.81
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.|[2]Leonard KA, et al. Discovery of a Gut-Restricted JAK Inhibitor for the Treatment of Inflammatory Bowel Disease. J Med Chem. 2020 Mar 26;63(6):2915-2929.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported